Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rohit Pal

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
European Journal of Medicinal Chemistry|October 10, 2021
Reactive metabolites of the anticonvulsant drugs and approaches to minimize the adverse drug reactionRohit Pal, Karanvir Singh, Shah Alam Khan, et al.
Current Neuropharmacology|August 4, 2021
Overview of Chemistry and Therapeutic Potential of Non-Nitrogen Heterocyclics as Anticonvulsant AgentsRohit Pal, Karanvir Singh, Joyson Paul, et al.
Chemistry & Biodiversity|August 11, 2023
Medicinal Chemistry Perspectives on Recent Advances in Src Kinase Inhibitors as a Potential Target for the Development of Anticancer Agents: Biological Profile, Selectivity, Structure-Activity RelationshipGhanshyam Teli, Rohit Pal, Lalmohan Maji, et al.
European Journal of Medicinal Chemistry|November 11, 2024
Next-generation cancer therapeutics: PROTACs and the role of heterocyclic warheads in targeting resistanceEbna Azizal Omar, Rajesh R, Pronoy Kanti Das, et al.
Bioorganic Chemistry|November 17, 2022
Discoidin domain receptor inhibitors as anticancer agents: A systematic review on recent development of DDRs inhibitors, their resistance and structure activity relationshipGanesh Prasad Shenoy, Rohit Pal, Gurubasavaraja Swamy Purwarga Matada, et al.
Bioorganic Chemistry|November 27, 2024
Recent advancements in mechanistic research, therapeutic potential, and structure-activity relationships of aurora kinase inhibitors in cancer therapiesGhanshyam Teli, Lalmohan Maji, Rohit Pal, et al.
Molecular Diversity|July 20, 2023
An updated literature on BRAF inhibitors (2018-2023)Lalmohan Maji, Ghanshyam Teli, Nulgumnalli Manjunathaiah Raghavendra, et al.
European Journal of Medicinal Chemistry|January 1, 2026
Medicinal chemistry perspective on quinazoline derivatives: Sustainable synthetic routes, anticancer evaluation, and SAR analysisSudarshini Dutta, R Rajesh, P M Gurubasavaraja Swamy, et al.
Chemistry & Biodiversity|December 3, 2025
Steroidal Scaffolds as Anticancer Agents: Evolution, FDA Approvals, Synthetic Derivatives, SAR Profiles, and Translational PerspectivesPrabhugouda Gugal, Hemalatha Kamurthy, Rohit Pal, et al.
Journal of Biomolecular Structure & Dynamics|May 9, 2023
An assessment of EGFR and HER2 inhibitors with structure activity relationship of fused pyrimidine derivatives for breast cancer: a brief reviewPrasad Sanjay Dhiwar, Gurubasavaraja Swamy Purawarga Matada, Rohit Pal, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
European Journal of Medicinal Chemistry|October 10, 2021
Reactive metabolites of the anticonvulsant drugs and approaches to minimize the adverse drug reactionRohit Pal, Karanvir Singh, Shah Alam Khan, et al.
Current Neuropharmacology|August 4, 2021
Overview of Chemistry and Therapeutic Potential of Non-Nitrogen Heterocyclics as Anticonvulsant AgentsRohit Pal, Karanvir Singh, Joyson Paul, et al.
Chemistry & Biodiversity|August 11, 2023
Medicinal Chemistry Perspectives on Recent Advances in Src Kinase Inhibitors as a Potential Target for the Development of Anticancer Agents: Biological Profile, Selectivity, Structure-Activity RelationshipGhanshyam Teli, Rohit Pal, Lalmohan Maji, et al.
European Journal of Medicinal Chemistry|November 11, 2024
Next-generation cancer therapeutics: PROTACs and the role of heterocyclic warheads in targeting resistanceEbna Azizal Omar, Rajesh R, Pronoy Kanti Das, et al.
Bioorganic Chemistry|November 17, 2022
Discoidin domain receptor inhibitors as anticancer agents: A systematic review on recent development of DDRs inhibitors, their resistance and structure activity relationshipGanesh Prasad Shenoy, Rohit Pal, Gurubasavaraja Swamy Purwarga Matada, et al.
Bioorganic Chemistry|November 27, 2024
Recent advancements in mechanistic research, therapeutic potential, and structure-activity relationships of aurora kinase inhibitors in cancer therapiesGhanshyam Teli, Lalmohan Maji, Rohit Pal, et al.
Molecular Diversity|July 20, 2023
An updated literature on BRAF inhibitors (2018-2023)Lalmohan Maji, Ghanshyam Teli, Nulgumnalli Manjunathaiah Raghavendra, et al.
European Journal of Medicinal Chemistry|January 1, 2026
Medicinal chemistry perspective on quinazoline derivatives: Sustainable synthetic routes, anticancer evaluation, and SAR analysisSudarshini Dutta, R Rajesh, P M Gurubasavaraja Swamy, et al.
Chemistry & Biodiversity|December 3, 2025
Steroidal Scaffolds as Anticancer Agents: Evolution, FDA Approvals, Synthetic Derivatives, SAR Profiles, and Translational PerspectivesPrabhugouda Gugal, Hemalatha Kamurthy, Rohit Pal, et al.
Journal of Biomolecular Structure & Dynamics|May 9, 2023
An assessment of EGFR and HER2 inhibitors with structure activity relationship of fused pyrimidine derivatives for breast cancer: a brief reviewPrasad Sanjay Dhiwar, Gurubasavaraja Swamy Purawarga Matada, Rohit Pal, et al.
Pageof 4